Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody

  title={Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody},
  author={Naoji Umemoto and Yoshinori Kato and T. Hara},
  journal={Cancer Immunology, Immunotherapy},
SummaryIn studies on (antitumor antibody)-drug conjugates as potential antitumor agents, the amide derivatives of methotrexate (MTX) with cysteine and with 2-mercaptoethylamine (cysteamine) (MTX-Cys and MTX-MEA, respectively) were linked via a disulfide bond with a monoclonal antibody (αMM46) to a mouse mammary tumor MM46 with attached 3-(2-pyridyldithio) propionyl groups to give conjugates of MTX with αMM46 (MTX-Cys-SS-αMM46 and MTX-MEA-SS-αMM46, respectively). These two conjugates are both… Expand
Preparation and in vitro cytotoxicity of a methotrexate‐anti‐MM46 monoclonal antibody conjugate via an oligopeptide spacer
A method was developed by which conjugates of methotrexate (MTX) with antibody were prepared via an oligopeptide spacer which, after internalization of the conjugates into the target cells, would beExpand
Synthesis and biological evaluation of disulfide-linked HPMA copolymer-mesochlorin e6 conjugates.
The synthesized conjugates demonstrated a time-dependent reductive cleavage with an accompanying increase in the quantum yield of singlet oxygen generation on exposure to DTT and hold promise as clinically relevant drug delivery systems for photodynamic therapy of cancer. Expand
Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: Anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues
Tumor-associated antigens can be suitable targets for antibody-drug conjugates even when present in normal tissues and in large quantities, provided that the antigen innormal tissues are inaccessible. Expand
Drug targeting by macromolecules without recognition unit?
Two examples of methotrexate and daunomycin conjugates will be discussed to show the effect of the chemical structure of branched chain polypeptides on the uptake and antitumour or antiparasitic (Leishmania donovani infection) efficacy of conjugate. Expand
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities.
This review focuses on understanding where and how the disulfide bond in the bioconjugate is reduced upon contact with biological milieu, which affects delivery design and the interpretation of the delivery strategies. Expand


Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates.
In combination with hydroxylamine treatment, insertion between MTX and IgG of a linkage capable of ready cleavage in lysosomes deserves exploitation as a method for making potent conjugates with less nonspecific activity. Expand
In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody.
The results support the idea that the selective cytotoxicity of aMM46:HSA:MTX is antibody directed and exhibited through lysosomal degradation of the conjugate. Expand
Monensin is obligatory for the cytotoxic action of a disulfide linked methotrexate-anti-transferrin receptor conjugate.
Results suggest that the ionophore causes antibody-drug conjugate to bypass the normal transferrin receptor cyclic pathway, allowing sufficient drug to reach, bind to, and inactivate intracellular dihydrofolate reductase. Expand
Production of a monoclonal antibody-methotrexate conjugate utilizing dextran T-40 and its biologic activity.
The results indicate that the MTX-(H-l) conjugate binds to the cell surface antigen by its antibody action and exerts greater MTX cytotoxicity than free MTX in vitro. Expand
Studies of methotrexate-monoclonal antibody conjugates for immunotherapy.
MTX-antibody complexes can be successfully produced and can be used for the immunotherapy of tumors and impaired the growth of established tumors in vivo. Expand
Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody
SummaryIn studies on antitumor antibody-cytotoxic drug conjugates as potential tumor-selective cytotoxic agents, methotrexate (MTX) was conjugated via its active ester derivative with a murineExpand
Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo.
The demonstrated superiority of the active ester method in producing active conjugates prompted us to use this technique for linking MTX to a rabbit IgG antibody against the mouse EL4 lymphoma. Expand
Disulfide spacer between methotrexate and poly(D-lysine). A probe for exploring the reductive process in endocytosis.
It is concluded that the reductive process through which methotrexate is released from the disulfide spacer occurs inside cells and not at the cell surface, requires neither acid pH nor lysosomal enzymes, and is not mediated by a glutathione-disulfide exchange reaction requiring high glutathion concentrations. Expand
Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells.
Results indicate that the MTX antibody conjugate binds specifically to F-9 cells, and is internalized and intracellularly degraded to release a small molecular active drug. Expand
Importance of the antigen-binding valency and the nature of the cross-linking bond in ricin A-chain conjugates with antibody.
Results suggest that divalency in antigen-binding and susceptibility of the cross-linking bond to cleavage by mercapto reagent are desirable for high potency. Expand